Welcome to our dedicated page for Integrated Biopharma news (Ticker: INBP), a resource for investors and traders seeking the latest updates and insights on Integrated Biopharma stock.
Integrated BioPharma, Inc. (INBP) is a nutraceutical-focused manufacturer engaged in the manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The company regularly issues detailed press releases on its quarterly and annual financial results, which are also furnished to the SEC on Form 8-K under Item 2.02.
News about INBP commonly covers revenue trends, operating income or loss, net income or loss, and earnings per share for specific quarters and fiscal years. Management commentary from the Co-Chief Executive Officers often highlights performance in the Contract Manufacturing Segment, the proportion of revenue derived from the company’s two largest customers, and efforts to expand the customer base while focusing on core businesses.
Investors following INBP news can expect recurring updates on revenue levels, cost of sales, gross profit, selling and administrative expenses, and other income or expense, as well as income tax expense or benefit. Releases also discuss revenue concentration in the Contract Manufacturing Segment and, in some periods, growth in warehousing and distribution activities within the nutraceutical business.
In addition to earnings-related announcements, company and SEC materials provide information on corporate governance events such as the annual meeting of stockholders, advisory votes on executive compensation and the frequency of such votes, and ratification of the independent auditor. Tracking this news stream helps readers understand how Integrated BioPharma’s financial performance, customer concentration and governance decisions evolve over time.
Integrated BioPharma (INBP) reported a strong performance for the quarter and fiscal year ending June 30, 2021. Revenues for Q4 reached $17.1 million, up 26.7% year-over-year, with net income of $4.5 million or $0.15 per share. For the fiscal year, total revenue was $63.6 million, a 20.5% increase, accompanied by net income of $8.0 million or $0.27 per share. Key customers in contract manufacturing accounted for 92% of revenues, demonstrating stable demand.
Integrated BioPharma (INBP) reported a 25.2% revenue increase for Q1 2021, totaling $17.1 million compared to Q1 2020. For the nine-month period, revenue reached $46.5 million, up 18.6% year-over-year. Operating income also rose from $1.0 million to $1.7 million for Q1, and net income increased from $0.9 million to $1.2 million during the same period. The company emphasized the consistency of revenue from its major customers, contributing 92% to total revenue.
Integrated BioPharma, Inc. (OTCQX: INBP) has launched an updated investors website aimed at enhancing shareholder engagement. Effective April 8, 2021, the site features current stock quotes, historical financial data, news, and events. Co-CEOs Riva Sheppard and Christina Kay emphasize that the reactivation of email subscription alerts will facilitate better communication with shareholders. The company focuses on manufacturing and distributing vitamins, nutritional supplements, and herbal products, ensuring transparency for investors.
Integrated BioPharma, Inc. (OTCQX:INBP) announced its financial results for Q2 2020, revealing revenue of $14.3 million, a slight increase from $14.2 million in Q2 2019. For the six-month period, revenue rose 14.8% to $29.4 million. The company reported net income of $1.2 million ($0.04 per share) for Q2 2020, up from $1.0 million ($0.03 per share) in 2019. Operating income remained stable at $1.2 million for both periods. The Co-CEOs highlighted consistency in revenue from their top two customers, making up 92% of total revenue.
Integrated BioPharma (OTCQB:INBP) announces a strong financial performance for Q3 2020, reporting revenue of $15.2 million, a significant increase of 33% from $11.4 million in Q3 2019. The company achieved an operating income of $1.5 million and a net income of $1.0 million ($0.04 per share), up from $0.3 million ($0.01 per share) the previous year. Notably, revenue from key customers remained stable, constituting 92% of total revenue. Eric Friedman joins the Board as a Class III director, contributing to future strategic developments.
Integrated BioPharma, Inc. (OTCQB:INBP) reported a 5.6% increase in revenues for the fiscal year ended June 30, 2020, reaching $52.8 million, compared to $50 million in 2019. Net income rose to $4.1 million or $0.14 per share, from $1.7 million or $0.06 per share the previous year. The operating income also increased to $3.3 million, reflecting a positive year amid COVID-19 challenges. Revenues from two major customers remained consistent, contributing approximately 92% of total revenue.